


Claims

1. A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval.
2. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval.
3. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval.
4. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy.
5. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy.
6. Use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer.
7. The therapeutic agent for a hormone-dependent cancer

according to Claim 1, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:



[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R¹ represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or -NR³R⁴ (wherein R³ and R⁴ may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R³ and R⁴ are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R² represents a monocyclic alcohol residue or a polycyclic alcohol residue].

8. The method for treating a hormone-dependent cancer according to Claim 2, wherein the steroid-sulfatase

inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I) described in Claim 7 or a pharmaceutically acceptable salt thereof.

9. The steroid-sulfatase inhibitor according to Claim 3, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I) described in Claim 7 or a pharmaceutically acceptable salt thereof.


10. The kit for treating according to Claim 4, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I) described in Claim 7 or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition according to Claim 5, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I) described in Claim 7 or a pharmaceutically acceptable salt thereof.

12. The use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy according to Claim 6, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I) described in Claim 7 or a pharmaceutically acceptable salt

thereof.

13. The therapeutic agent for a hormone-dependent cancer according to Claim 1, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, a compound represented by Formula (IA) or a pharmaceutically acceptable salt thereof:



(wherein -O-R², R³, and R⁴ have the same meanings as defined above, respectively).

14. The method for treating a hormone-dependent cancer according to Claim 2, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IA) described in Claim 13 or a pharmaceutically acceptable salt thereof.

15. The steroid-sulfatase inhibitor according to Claim 3, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IA) described in Claim 13 or a pharmaceutically acceptable salt thereof.


16. The kit for treating according to Claim 4, wherein the steroid-sulfatase inhibitor is a composition comprising, as

an active ingredient, the compound represented by Formula (IA) described in Claim 13 or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition according to Claim 5, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IA) described in Claim 13 or a pharmaceutically acceptable salt thereof.

18. The use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy according to Claim 6, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IA) described in Claim 13 or a pharmaceutically acceptable salt thereof.

19. The therapeutic agent for a hormone-dependent cancer according to Claim 1, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, a compound represented by Formula (IB) or a pharmaceutically acceptable salt thereof:



[wherein R^3 and R^4 have the same meanings as defined above, respectively; R^5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, $-\text{NR}^6\text{R}^7$ (wherein R^6 and R^7 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), $-\text{OR}^8$ (wherein R^8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or $-\text{SR}^{8A}$ (wherein R^{8A} has the same meaning as R^8 defined above)].

20. The method for treating a hormone-dependent cancer

according to Claim 2, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IB) described in Claim 19 or a pharmaceutically acceptable salt thereof.

21. The steroid-sulfatase inhibitor according to Claim 3, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IB) described in Claim 19 or a pharmaceutically acceptable salt thereof.

22. The kit for treating according to Claim 4, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IB) described in Claim 19 or a pharmaceutically acceptable salt thereof.

23. The pharmaceutical composition according to Claim 5, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IB) described in Claim 19 or a pharmaceutically acceptable salt thereof.

24. The use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy according to Claim 6, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (IB)

described in Claim 19 or a pharmaceutically acceptable salt thereof.

25. The therapeutic agent for a hormone-dependent cancer according to Claim 1, 7, 13, or 19, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a luteinizing hormone-releasing hormone (LH-RH) agonist.

26. The method for treating a hormone-dependent cancer according to Claim 2, 8, 14, or 20, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

27. The steroid-sulfatase inhibitor according to Claim 3, 9, 15, or 21, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

28. The kit for treating according to Claim 4, 10, 16, or 22, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation

comprising progesterone, and a preparation comprising a LH-RH agonist.

29. The pharmaceutical composition according to Claim 5, 11, 17, or 23, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

30. The use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy according to Claim 6, 12, 18, or 24, wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

31. The therapeutic agent for a hormone-dependent cancer according to Claim 1, 7, 13, or 19, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

32. The method for treating a hormone-dependent cancer according to Claim 2, 8, 14, or 20, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

33. The steroid-sulfatase inhibitor according to Claim 3, 9, 15, or 21, wherein the agent for hormone therapy is an

antiestrogen agent and/or an aromatase inhibitor.

34. The kit for treating according to Claim 4, 10, 16, or 22, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

35. The pharmaceutical composition according to Claim 5, 11, 17, or 23, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

36. The use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy according to Claim 6, 12, 18, or 24, wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.